Accrued Liabilities and Other Payables (Details Textual)	12 Months Ended
Dec. 31, 2019 USD ($)
Accrued Liabilities and Other Payables (Textual)
Strategic partnership agreement, description	In accordance with the strategic partnership agreement with Weill Cornell's cGMP Cellular Therapy Facility and Laboratory signed on August 6, 2018, the Company provides $400,000 annually to Weill Cornell's cGMP Cellular Therapy Facility and Laboratory to support the co-development projects. In addition, the Company will on an annual basis send one scientist or clinician to Weill Cornell's cGMP Cellular Therapy Facility and Laboratory to receive relevant training for three to six months.
Accrued and unpaid research and development fees	$ 150,000

Amount of expenses incurred but not yet paid classified as other.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Name:	us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant